Brought to you by 
Eli Lilly out-licenses migraine candidate to CoLucid Pharmaceuticals
18 Jan 2017
Executive Summary
CoLucid Pharmaceuticals Inc., a start-up founded just a few months ago, in-licensed its first candidate from Eli Lilly & Co., the Phase I small-molecule 5HT1F agonist LY573144 for migraine and headache pain. CoLucid holds exclusive worldwide development and commercialization rights, along with the right to sublicense.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eli Lilly out-licenses migraine candidate to CoLucid Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice